Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 3/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.51 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.51 |
| ▸ | PRKAA2 | P54646 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.44 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.44 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4917352 | 0.85 | SMN1; SMN2 (0.49) | CHRM3CHRM4CXCR3MEN1KMT2A | |
| SCHEMBL4924772 | 0.83 | ACKR3 (0.53) | CHRM3CHRM4CXCR3MEN1KMT2A | |
| SCHEMBL4924848 | 0.79 | CHRM3 (0.51) | CHRM3CHRM4CXCR3PRKAA2MEN1 | |
| SCHEMBL4923485 | 0.79 | ALDH1A1 (0.59) | MEN1KMT2A | |
| SCHEMBL4922789 | 0.78 | TSHR (0.60) | CHRM4MEN1KMT2AEPHX2 | |
| SCHEMBL4917794 | 0.75 | LMNA (0.52) | MEN1KMT2A | |
| SCHEMBL4917811 | 0.74 | PPARG (0.57) | MEN1KMT2A | |
| SCHEMBL5577491 | 0.74 | CHRM3 (0.56) | CHRM3CHRM4CXCR3PRKAA2MEN1 | |
| SCHEMBL4920802 | 0.74 | SMN1; SMN2 (0.51) | MEN1KMT2A | |
| SCHEMBL13205358 | 0.73 | CXCR3 (0.86) | CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081824-A1 | Substituted piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081824-A1 | Substituted piperidines as modulators of chemokine receptor activity | CCR1, CCR3, CCR2 | CHRM3 37/4885CHRM4 101/4885CXCR3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.